WP01 Longitudinal Onset and Course Cohort Studies (Leader: UCL / A. Schrag): Objectives
|
|
- Stephanie Webster
- 6 years ago
- Views:
Transcription
1 To facilitate the organisation and management, the project is structured in Work packages which together comprise the project. EMTICS consists of 12 work packages (WPs). Each WP is carried out by a varying number of involved parties. The WP leader supervises and adjusts the process flow and works closely with the project office. The activity of the WP will be overseen by the chair of the working group. WP01 Longitudinal Onset and Course Cohort Studies (Leader: UCL / A. Schrag): 1 / 7
2 Establish clinical cohort studies ONSET and COURSE. Establish whether the childhood onset of tics and/or obsessive-compulsive symptoms in first-degree relatives of patients with TS or another chronic tic disorder is associated with pharyngeal GAS carriage or infection. Develop prediction models for the risk of onset of symptoms in first-degree relatives of patients with TS or another tic disorder, integrating information on demographic and clinical information, psychosocial stress, perinatal factors and environmental exposures. Examine the effects of exposure to GAS in the form of pharyngeal carriage or infection upon the risk of developing clinically relevant exacerbations of tics and/or obsessivecompulsive symptoms in children affected by TS or chronic tic disorder. WP02 Microbiological Characterisation (Leader: ISS-RC / R. Creti): Assess GAS serotype distribution by performing emm sequence typing on the bacterial isolates received from both WP01 and WP07 studies as well as from controls. Determine the GAS bacterial population genetic structure both by a whole chromosomal DNA analysis method as Pulsed Field Gel Electrophoresis (PFGE) and by a sequencebased method as Multi Locus Sequence Typing (MLST). Evaluate the distribution of specific bacterial virulence genes, including their allelic variants, and their potential association with tic symptoms by Polymerase Chain Reaction (PCR) screening and DNA sequencing. WP03 Anti-Streptococcal Immune Response (Leader: NVD / I. Margarit Y Ros): Investigate antibody response profiles to a large panel of GAS surface antigens in patients with a tic disorder and in healthy relatives recruited in the ONSET study (WP01), with particular attention to immune response variations in patients relatives experiencing first onsets of tics (ONSET study). Identify a subset of GAS antigens eliciting high antibody responses in patients with a tic disorder compared to healthy individuals (from WP01). Investigate the effect of antibiotic treatment in patient antibody response profiles, in 2 / 7
3 relation to microbiological data (WP02) and clinical observations (WP07). WP04 Immune Measurements (Leader: LMU / N. Müller): Identify non-streptococcal bacterial, viral and other microbial infections as potential environmental risk factors for TS/OCD. In depth analyse the cellular and humoral (antibodies, cytokines, CRP) immune response against the identified potentially causative microbes. Measure the effect of anti-neuronal glycolytic enzymes (NGE) antibodies on membrane excitability on neuronal cell lines. Investigate alteration of the kynurenine pathway, which has functional interconnections between the immune system and neurotransmitter systems. WP05 Animal Model (Leader: ISS-GL / G. Laviola): Develop a mouse test battery aimed at mimicking behavioural (stereotypical, compulsive and perseverative patterns), immune and brain abnormalities isomorphic to clinical symptoms of TS, as a function of induced autoimmunities. Expose candidate mouse strains to passive transfer of streptococcus-induced antibodies, characterised by neuronal cross-reactivity (from both humans and animals) and validate its consequences on the test battery developed under objective 1. Identify the prototypical mouse strain that shows the highest isomorphism with TS clinical symptoms in response to streptococcus-induced antibodies. Active immunisation with GAS homogenates and/or pools of streptococcal antigens showing high antibody responses in patients with TS according to WP02 and WP03. The target mouse strain will thereof display appropriate antibody titres, T cell immunity, and brain lesions characteristic to autoimmunity. Evaluate whether the abnormalities identified under objective 4 are aggravated by psychosocial stress (in collaboration with WP08). 3 / 7
4 WP06 Genetics & Gene Expression (Leader: DUTH / P. Paschou): Identify genes and gene pathways that influence the pathogenesis of tics and obsessivecompulsive symptoms. Examine the gene pathways that influence the clinical course of tic disorders and that are activated upon symptom exacerbations. Explore the complex interaction between environment, autoimmunity and genetics related to the onset and clinical course of the disorder spectrum. Develop prediction models for the risk of onset of symptoms in first-degree relatives of patients with TS and other chronic tic disorders, integrating information on genetic background and environmental exposures. Develop prediction models describing the clinical course of TS and other chronic tic disorders and associated obsessive-compulsive symptoms, integrating individual genetic profiles with specific environmental exposures. Establish a European biobank of samples for the study of tic disorders and associated comorbidities. Develop novel data-mining and statistical methodology for the investigation of the aetiology of complex disorders, uncovering involved gene networks and geneenvironment interactions. WP07 Treatment (Leader: UniROMA / F. Cardona): Test the hypothesis that antibiotic treatment of GAS colonisation compared to placebo is associated with a larger reduction of tic and associated neuropsychiatric symptoms in the short term (1 month; primary objective). This will be determined by mean change from the baseline to endpoint (1 month) of the primary outcome measure, the Yale Global Tic Severity Scale (YGTSS); clinician based ratings of associated neuropsychiatric symptoms will be secondary outcome measures. Test the hypothesis that antibiotic treatment of GAS colonisation is superior to placebo in the long term (1 year) reduction of tic and associated neuropsychiatric symptoms in patients affected by TS or another chronic tic disorder (secondary objective). This will be determined by last observation carried forward (LOCF) mean change from baseline to endpoint (1 year) on the primary outcome measure, the YGTSS; clinician based ratings of associated neuropsychiatric symptoms will be secondary outcome measures. Investigate the effects of antibiotic treatment on patient s immune responses to GAS antigens (in cooperation with WP03). Investigate the influence of possible moderators on treatment outcome; we will 4 / 7
5 investigate the role of demographic and clinical variables; of chronic psychosocial stress (in cooperation with WP08); and of GAS colonisation characteristics (in cooperation with WP02). WP08 Psychosocial Stress (Leader: TUD / V. Roessner): Establish whether chronic psychosocial stress assessed by rating scales as well as physiological parameters has an impact (A) on childhood onset of tics and/or obsessivecompulsive symptoms in at risk individuals as well as (B) on clinically relevant exacerbations of tics and/or obsessive-compulsive symptoms in children affected by TS or another chronic tic disorder (in collaboration with WP01). Evaluate the functioning of the hypothalamic-pituitary-adrenal axis stress system in children with TS or another chronic tic disorder by assessing the cortisol awaking response (CAR), a short diurnal profile as well as the stress reactivity to a standardised psychosocial stressor in a subsample of (A) and (B). Investigate the moderating impact of chronic psychosocial stress on the effectiveness of treatment of GAS colonisation with antibiotics on tics and/or obsessive-compulsive symptoms (in cooperation with WP07). Explore possible relationships between psychosocial stress and (A) the innate and adaptive immune system (in collaboration with WP04) and (B) occurrence and duration of new GAS colonisations in children with a tic disorder (COURSE study) and as yet unaffected high risk children (ONSET study; in collaboration with WP01). Evaluate the basal levels of corticosteroids (in plasma and hair samples) in the mouse model of TS and their variation in response to psychosocial stress, in collaboration with WP05. WP09 Data Management (Leader: BHAM / A. Cavanna): Establish an effective electronic data capture system for the cohort studies described in WP01 and the treatment study of WP07. Enable coupling of measurements obtained in WPs 02, 04, 06 and 08 with the electronic data capture system. Establish a Europe-wide database for the longitudinal cohort studies described in WP01 5 / 7
6 and the associated measurements obtained in WPs 02, 04, 06 and 08. WP10 Training and Dissemination (Leader: UNICT / R. Rizzo): The specific training objectives will be: Assure an appropriate conduct of research in accordance with Good Clinical Practice (GCP). Provide EMTICS clinicians (including young female scientists and scientists from Eastern Europe) advanced training in Clinical Rating Files (CRF) and psychiatric assessment instruments developed by WP01 and WP08; and to check quality standards with respect to GCP. Provide EMTICS scientists advanced training in epidemiology and clinical aspects of Group A streptococcal (GAS) infections and non suppurative sequelae. Harmonise and improve, through ad hoc training courses and two external quality assessments (EQA), the microbiological methods used by different centres to isolate GAS from carriers with low bacterial density. This is essential to guarantee reliability of results. Particular attention will be devoted to the training of young female scientists and scientists from Eastern Europe in order to encourage their participation in research projects and improve their professional development. The specific dissemination objectives will be: Primary objective: Coordinate dissemination of project progress and results Secondary objectives: Coordinate the further development and regular updating of the dissemination and exploitation strategy. Generate information kits for investigators and participants. Identify relevant target group for dissemination of aims, methods and results of EMTICS project. Communicate with professionals, patient organisations and the general public. 6 / 7
7 Powered by TCPDF ( Workpackages in Detail WP11 Ethics (Leader: SCMCI / A. Apter): Set the highest standards for the ethical aspects of the proposed human studies complying with EU regulations and all participating countries. Allow appropriate Informed Consent (parent/ guardian) and assent (children/adolescents). Protect research participants confidentiality. Ensure care and protection of human research participants. Ensure adherence to the above determined ethical standards, thus insuring the EMTICS project will be carried out in compliance with fundamental ethical principles as stated by the European Union and all participating countries. Ensure animal use and experimentation (in association with WP05), according to the 3Rs principle. WP12 Project Management (Leader: concentris / S. Stöber): Make EMTICS achieve its objectives and to deliver in time, budget and quality its milestones and deliverables. Help the consortium abide by the regulations and contractual obligations according to the grant agreement, its annexes and the consortium agreement. Look after the project`s finances and to report them properly to the European Commission. Establish a communication infrastructure which enables the partners to communicate efficiently and to stay connected for the run-time of the project. Preserve the rights of the partners regarding intellectual property and to act as a mediator in case of disputes. 7 / 7
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL INTERIM REPORT 02_2013
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EXECUTIVE AGENCY FOR HEALTH AND CONSUMERS Health unit Contract number: 2010 21 02 Acronym: QUANDHIP INTERIM REPORT 02_2013 Proposal title: Quality
More informationCharacterisation of group A streptococcal (GAS) isolates from children with tic disorders
Indian J Med Res 119 (Suppl) May 2004, pp 174-178 Characterisation of group A streptococcal (GAS) isolates from children with tic disorders R. Creti, F. Cardona*, M. Pataracchia, C. von Hunolstein, G.
More informationWhat s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey
What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey Liisa Valsta Data Collection and Exposure Unit What s s on the menu in Europe? Background Attempts
More informationState of The Art Pieter Hoekstra
State of The Art Pieter Hoekstra Tourette syndrome: an update on newest findings on treatment and pathophysiology Gilles de la Tourette syndrome: an update Pieter Hoekstra UMCG & Accare p.hoekstra@accare.nl
More informationIntroduction. Keywords Genetics Longitudinal Obsessive compulsive disorder Stress Streptococcal infection Tourette syndrome
https://doi.org/10.1007/s00787-018-1190-4 ORIGINAL CONTRIBUTION European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation
More informationIMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationJPI A healthy diet for a healthy life. JPI: concept and benefits Vision Research areas Governance
JPI A healthy diet for a healthy life JPI: concept and benefits Vision Research areas Governance European research area Today, 85% of public R&D is programmed, financed, monitored and evaluated at national
More informationTable Of Content. Policy Action and Information for Rare Diseases in Europe... 2 Summary... 3 Coordinator, Leader contact and partners...
Table Of Content Policy Action and Information for Rare Diseases in Europe... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Kontaktudvalget for Mindre Sygdoms-og handicapforeninger (KMS)...
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationNew proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus
New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus Jacqueline Fryer Division of Virology, NIBSC National Institute for Biological Standards and Control Assuring the quality
More informationPatrícia Pissarra RARHA Project Leader. Luxembourg. 7 th October 2016
Patrícia Pissarra RARHA Project Leader Luxembourg 7 th October 2016 Wp4 The work is divided into two tasks Task 1: rarha seas (standardised european alcohol survey) new alcohol survey to collect comparable
More informationPediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC Objectives Learn the diagnostic criteria of Pediatric Autoimmune
More informationrare diseases research through National Plans and Strategies
Recommendations to support rare diseases research through National Plans and Strategies Dr Domenica Taruscio EUROPLAN Coordinator Director of the Italian Centre for Rare Diseases, Italian National Institute
More informationGender Aspects in R&I Horizon Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency
Gender Aspects in R&I Horizon 2020 Stephanie Rammel Gender Expert in H2020 and ERA FFG - Austrian Research Promotion Agency This presentation is about Horizon 2020: where are gender aspects relevant for
More informationAn Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents
An Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents Kyle Williams, MD, PhD Director, Pediatric Neuropsychiatry and Immunology Program Massachusetts General Hospital
More informationFit4RareFit4All Conference Cluj - Napoca 3-4 September 2017
Fit4RareFit4All Conference Cluj - Napoca 3-4 September 2017 Rare diseases registries as key tools in research and public health Domenica Taruscio Director, National Centre for Rare Diseases Istituto Superiore
More informationInterventions To Improve Antibiotic Prescribing for Uncomplicated Acute Respiratory Tract Infections
Clinician Summary Breathing Conditions Respiratory Tract Infections Interventions To Improve Antibiotic Prescribing for Uncomplicated Acute Respiratory Tract Infections Focus of This Summary This is a
More informationAmaze Position Description
Amaze Position Description Position Title: Manager, Information and Support Programs Division: Information and Support Programs Reporting To: CEO Effective Date: 01/12/2018 Direct Reports: 3 FTE: 1.0 Amaze
More informationEpiCARE a network for rare and complex epilepsies
Grant agreement no. 769051 EpiCARE a network for rare and complex epilepsies HP-ERN-2016 European Reference Networks / Framework Partnership Agreement D15.1: Proposal for EpiCARE clinical database Work
More informationPREPARE. Herman Goossens, Coordinator. Panel discussion, GLoPID-R meeting, Sao Paulo, Brazil December 1, 2016
PREPARE Herman Goossens, Coordinator Panel discussion, GLoPID-R meeting, Sao Paulo, Brazil December 1, 2016 PREPARE is funded by the European Commission under grant number 602525 Agenda Network structure
More informationTable Of Content. Page 1/8
Table Of Content 22nd Conference: Changing perceptions, practice and policy... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04-00 - Programme and book of abstracts (EN)...
More informationCLINICAL REGISTRIES Use and Emerging Best Practices
CLINICAL REGISTRIES Use and Emerging Best Practices Tim Friede Department of Medical Statistics University Medical Center Göttingen DZHK (German Center for Cardiovascular Research) OUTLINE Background:
More informationPaolo G. Casali Annalisa Trama
Paolo G. Casali Annalisa Trama Objectives With regard to RCs in the EU, to improve: 1. Epidemiological surveillance 2. Quality of care through ERNs 3. Clinical practice guidelines 4. Innovation 5. Medical
More informationTable Of Content. European Rare Kidney Diseases Reference Network... 2 Summary... 3 Work Package... 9
Table Of Content European Rare Kidney Diseases Reference Network... 2 Summary... 3 Work Package... 9 Network Management... 9 Promote cross-border expert healthcare... 9 Harmonize specialized care... 9
More informationStockpiling of H5N1 vaccines
Stockpiling of H5N1 vaccines Norbert W. Hehme EVM Influenza Pandemic Working Group EU-Commission Workshop on Stockpiling of Medicinal Products February 21/22, 2008 European Vaccine Manufacturers 1 (EVM)
More information2017 Year-end Results and Corporate Update
NASDAQ: GNMX 2017 Year-end Results and Corporate Update March 13, 2018 2018, Aevi Genomic Medicine Forward-Looking Statement This presentation includes certain estimates and other forward-looking statements
More informationCitation for published version (APA): van Munster, B. C. (2009). Pathophysiological studies in delirium : a focus on genetics.
UvA-DARE (Digital Academic Repository) Pathophysiological studies in delirium : a focus on genetics van Munster, B.C. Link to publication Citation for published version (APA): van Munster, B. C. (2009).
More informationIntroduction. Paolo G. Casali
Introduction Paolo G. Casali paolo.casali@istitutotumori.mi.it rare diseases rare diseases rare cancers cancer rare cancers Rare cancers childhood Rare cancers childhood haematological Rare cancers childhood
More informationMental Health. Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation
European efforts in Mental Health research Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation European Commission Conference on Psychotherapy in Europe EP, Brussels 9 February 2012
More informationTable Of Content. SSI_FY Summary... 3 Coordinator, Leader contact and partners... 7 Outputs... 8
Table Of Content SSI_FY2014... 2 Summary... 3 Coordinator, Leader contact and partners... 7 Outputs... 8 D01 - EuroMOMO system (EN)... 8 D02 - EuroMOMO website (EN)... 8 D03 - End of influenza season mortality
More informationMolecular typing insight on diversity and antimicrobial resistance of Campylobacter jejuni from Belgian chicken meat
Molecular typing insight on diversity and antimicrobial resistance of Campylobacter jejuni from Belgian chicken meat Ihab Habib Ghent University Department of Public Health and Food Safety. Contents: Molecular
More informationTable Of Content. Elderly Network on Ageing and Health... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...
Table Of Content Elderly Network on Ageing and Health... 2 Summary... 3 Coordinator, Leader contact and partners... 5 Istituto Nazionale per lo Studio e la Cura dei Tumori (INSCT)... 5 Deutsches Institut
More informationTable Of Content. Annex 1: Conference report... 7 Annual project reports (URL)... 7 Original Full Information (Dec 2008)... 7.
Table Of Content Alcohol Policy Network in the Context of a Larger Europe: Bridging the Gap... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 Annex 1: Conference report... 7
More informationEU REFERENCE LABORATORIES FOR AVIAN INFLUENZA AND NEWCASTLE DISEASE
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL G2- Animal Health 04 Veterinary Control programmes SANCO/7048/204 Draft Working document EU REFERENCE LABORATORIES FOR AVIAN INFLUENZA AND NEWCASTLE
More informationDevelopment of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
More informationCOUNCIL RECOMMENDATION of 2 December 2003 on cancer screening (2003/878/EC)
L 327/34 COUNCIL RECOMMDATION of 2 December 2003 on cancer screening (2003/878/EC) THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationManaging Tourette Syndrome
Managing Tourette Syndrome 1 / 6 2 / 6 3 / 6 Managing Tourette Syndrome Classroom Strategies and Techniques for Students with Tourette Syndrome. Managing Tourette Syndrome or a Tic Disorder in the classroom
More informationFinal Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052
Final Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052 1- Title of Study: The prevalence of neuropsychiatric disorders in children and adolescents on an inpatient treatment unit:
More informationMEETING REPORT INTERCONNECT: A GLOBAL INITIATIVE ON GENE-ENVIRONMENT INTERACTION IN DIABETES AND OBESITY.
MEETING REPORT INTERCONNECT: A GLOBAL INITIATIVE ON GENE-ENVIRONMENT INTERACTION IN DIABETES AND OBESITY. Funded by EU FP7 grant agreement 602068 Monday 12 September 2016, European Association for the
More informationTable Of Content. Invasive Bacterial Infections Surveillance in the European Union... 2 Summary... 3 Coordinator, Leader contact and partners...
Table Of Content Invasive Bacterial Infections Surveillance in the European Union... 2 Summary... 3 Coordinator, Leader contact and partners... 5 National School of Public Health... 5 National Institute
More informationPanCareSurFup Bulletin, Issue nr. 5
March 2014 PanCareSurFup Bulletin, Issue nr. 5 PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Dear Friends, Since the last Bulletin in December 2013, the project has been busy
More informationCollaborative Project of the 7th Framework Programme. WP6: Tools for bio-researchers and clinicians
G.A. nº 270086 Collaborative Project of the 7th Framework Programme WP6: Tools for bio-researchers and clinicians Deliverable 6.1: Design of Inference Engine v.1.0 31/10/2011 www.synergy-copd.eu Document
More informationPrevalence/incidence of maternal group B streptococcal colonisation in European countries A systematic review
Prevalence/incidence of maternal group B streptococcal colonisation in European countries A systematic review Egle Barcaite, MD, PhD student Department of Obstetrics and Gynaecology, Kaunas University
More informationTowards a coordinated risk assessment framework?
Towards a coordinated risk assessment framework? Zsuzsanna Jakab, ECDC Director 3 rd meeting of the Chairs of the Scientific Committees and Panels Stockholm, 6-7 November 2007 ecdc.europa.eu Content of
More informationNetworking Clinical Trials Anna Shevlin, Clinical Trial Liaison Officer
Networking Clinical Trials Anna Shevlin, Clinical Trial Liaison Officer HRB CRCI International Clinical Trial Networks Networking Clinical Trials Clinical Research Infrastructure Disease Clinical Research
More informationHealth Programme support to the European Action Plan HIV/AIDS
Health Programme 2008-2013 support to the European Action Plan HIV/AIDS 2009-2012 Executive Agency for Health and Consumers EAHC Cinthia Menel Lemos Cinthia.menel-lemos@ec.europa.eu What are the news?
More informationWhole genome sequencing & new strain typing methods in IPC. Lyn Gilbert ACIPC conference Hobart, November 2015
Whole genome sequencing & new strain typing methods in IPC Lyn Gilbert ACIPC conference Hobart, November 2015 Why do strain typing? Evolution, population genetics, geographic distribution 2 Why strain
More informationTable Of Content. Appropriate care paths for frail elderly patients: a comprehensive model... 2 Summary... 3 Work Package... 7
Table Of Content Appropriate care paths for frail elderly patients: a comprehensive model... 2 Summary... 3 Work Package... 7 Coordination of the project... 7 Dissemination of the project... 7 Evaluation
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationDUMFRIES AND GALLOWAY ALCOHOL AND DRUG PARTNERSHIP; PRIORITY ACTIONS AND
DUMFRIES AND GALLOWAY ALCOHOL AND DRUG PARTNERSHIP; PRIORITY ACTIONS 2013-14 AND 2014-15 RECOMMENDATION/WORKPLAN CURRENT POSITION IN D & G PLAN 1. Annual Report 1.1 Develop robust reporting mechanisms
More informationENYPAT European Network on Young People and Tobacco Final Report
ENYPAT European Network on Young People and Tobacco Final Report Grant agreement no SPC.2002412 Background ENYPAT is based at the National Public Health Institute (KTL) in Finland. ENYPAT is supported
More informationComplicações neurológicas pós infecção por estreptococos (mitos e verdades) Silvia Tenembaum
Complicações neurológicas pós infecção por estreptococos (mitos e verdades) Silvia Tenembaum Proposed pathophysiology of immune-mediated disorders Infection Tumor other Genetic predisposition 1. Molecular
More informationSupplementary Table 1 - Grand priority candidates: Ranking based on percentage of votes received from GP-TCM members and external participants
Supplementary Table 1 - Grand priority candidates: based on percentage of votes received from members and external participants Grand Priorities 1 72.4 7-8 48.6 High-quality research to evaluate the quality
More informationStreptococcal Pharyngitis
Streptococcal Pharyngitis Guideline developed by JC Beavers, MD, in collaboration with the ANGELS Team. Last reviewed by JC Beavers, MD on November 2, 2016. Preface Streptococcal pharyngitis (ie, strep
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationFirst Interim Report to the European Commission DG-SANCO for: Grant Agreement No.: (790655) EAIS. December Annex 2
First Interim Report to the European Commission DG-SANCO for: Grant Agreement.:2005112 (790655) EAIS. December 2006 Annex 2 European Autism Information System (EAIS) Project: Design of a Prevalence study.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationListeria whole-genome-sequencing EFSA Project. Anses Statens Serum Institut Public Health England University of Aberdeen
Listeria whole-genome-sequencing EFSA Project Anses Statens Serum Institut Public Health England University of Aberdeen Closing gaps for performing a risk assessment on Listeria monocytogenes in ready-to-eat
More informationImmunological evaluation of nextgeneration. Othmar G Engelhardt
Immunological evaluation of nextgeneration influenza vaccines Othmar G Engelhardt Today s presentation Evaluation of current influenza vaccines European regulatory guidelines Evaluation of novel vaccines
More informationNeuropsychiatric Disorders And Infection
Neuropsychiatric Disorders And Infection 1 / 6 2 / 6 3 / 6 Neuropsychiatric Disorders And Infection Objective: This study is designed to test the safety and efficacy of intravenous immunoglobulin (IVIG)
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationSwiss National Strategy on Open Access
Swiss National Strategy on Open Access Preamble In a letter dated 4 December 2015, the State Secretariat for Education, Research and Innovation (hereinafter SERI) commissioned swissuniversities to elaborate,
More informationP A N D A S. What is. Fact or Fiction PANDAS: Michael E. Pichichero, MD. Rochester General Hospital. Rochester, New York. Research Institute
PANDAS: Fact or Fiction Michael E. Pichichero, MD Director Rochester General Hospital Research Institute and Legacy Pediatrics Rochester, New York What is P A N D A S Swedo SE. Am J Psychiatry. 1998;155:264-271.
More informationPediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline
Pediatric Primary Care Mental Health Specialist Certification Exam Detailed Content Outline Description of the Specialty The Pediatric Primary Care Mental Health Specialist (PMHS) builds upon the Advanced
More informationReport of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland,
Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, 2011-2013 1. Background Streptococcus pneumoniae is a major cause of life-threatening infections
More informationProgramme Specification
Programme Specification Title: Forensic Science Final Award: Master of Science (MSc) With Exit Awards at: Master of Science (MSc) Postgraduate Certificate (PG Cert) Postgraduate Diploma (PG Dip) To be
More informationRegulatory Challenges for Influenza Vaccines 1
Regulatory Challenges for Influenza Vaccines 1 Regulatory Challenges for Influenza Vaccines Leonoor Wijnans - Influenza Summer School Siena, 19 July 2012 Regulatory challenges for influenza vaccines Regulatory
More informationCorporate Presentation April 2018
NASDAQ: GNMX Corporate Presentation April 2018 2018, Aevi Genomic Medicine Forward-Looking Statement This presentation includes certain estimates and other forward-looking statements within the meaning
More information- STATEMENT OF WORK - Task Authorization (TA) 37 FOR SUBCONTRACT WITH CIMVHR
1. NUMBER TITLE OF TASK AUTHORIZATION TA 37 Role of Neuroinflammation in Mental Disorders: Application of Multimodal Neuroimaging in the Assessment of Military PTSD. 2. VALIDATION OF SCOPE OF CONTRACT
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationThe prognosis of Tourette syndrome: implications for clinical practice
The prognosis of Tourette syndrome: implications for clinical practice Nadiya Hassan a Andrea E. Cavanna, MD, PhD a,b a The Michael Trimble Neuropsychiatry Research Group, Department of Neuropsychiatry,
More informationRetina International General Assembly Auckland, New Zealand
Retina International General Assembly 2018 - Auckland, New Zealand Thursday, February 8th, 2018 Location: University of Auckland Business School Owen G Glenn Building, 12 Grafton Road, Auckland, 1010 Room:
More informationCampylobacter: the actual status and control options
Campylobacter: the actual status and control options Prof. Jaap A. Wagenaar, DVM, PhD Dept. Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands
More information3135th JUSTICE and HOME AFFAIRS Council meeting Brussels, 13 and 14 December 2011
COUNCIL OF THE EUROPEAN UNION Council conclusions on the vision for European Forensic Science 2020 including the creation of a European Forensic Science Area and the development of forensic science infrastructure
More informationA multi-stakeholder partnership initiative. 10 February 2012
A multi-stakeholder partnership initiative 10 February 2012 1 History 39 recommendations on stakeholder actions and public policies:» 8 addressing regulatory barriers in rare cancer care» 11 addressing
More informationEUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY
Ref. Ares(2016)5909621-13/10/2016 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationEMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
More informationA progress report on the Joint Programming Initiative
A progress report on the Joint Programming Initiative In April 2010, Alzheimer Europe talked about the aims of the Joint Programming Initiative on Neurodegenerative Diseases (JPND) with the Initiative
More informationMoving towards 2020 priorities for Public Health for the years Health and Consumers
Moving towards 2020 priorities for Public Health for the years 2013-20 Health in the MFF 2014-2020 Commission proposal for the Health for Growth Programme 2014-2020 http://ec.europa.eu/health/programme/policy/index_en.htm
More informationDiscovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies
Discovery and validation of novel Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies Dr. Angela Wittelsberger, IMI IMI webinar 29.04.2016 Today s webinar Will cover all aspects of the
More informationAction Plan A1 ACTION GROUP Prescription and adherence to treatment
Action Plan A1 ACTION GROUP Prescription and adherence to treatment What is the Action Plan A1 AG about? Objectives 1. Improve patients' adherence 2. Empowerment 3. Contribute to the improvement of adherence
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationKyle Williams, MD, PhD Director, Pediatric Neuropsychiatry and Immunology Program Massachusetts General Hospital For Children
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS): An Inflammatory Hypothesis for Pediatric Obsessive Compulsive Disorder Kyle Williams, MD, PhD Director,
More informationSurveillance and outbreak investigation of Shiga toxin-producing Escherichia coli using whole genome sequencing- time for a change!
Surveillance and outbreak investigation of Shiga toxin-producing Escherichia coli using whole genome sequencing- time for a change! Dr Marie Anne Chattaway Deputy Head STEC Laboratory Gastrointestinal
More informationNEWSLETTER Partners. 43 Months WPs Deliverables. 8 Use Cases Companies RTDs. Contents. Keywords
Welcome to the first issue of the OActive Newsletter! NEWSLETTER Issue 1: December 2018 Contents 1. OActive at a glance 2. OActive website, video & milestones 3. OActive Physical Meetings 4. Attendance
More informationReflection paper on assessment of cardiovascular safety profile of medicinal products
25 February 2016 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on assessment of cardiovascular safety profile of medicinal products Draft agreed by Cardiovascular
More information1. The Working Party on Public Health discussed and agreed the draft Council conclusions as set out in the Annex.
Council of the European Union Brussels, 26 November 2015 (OR. en) 14395/15 SAN 391 NOTE From: To: Subject: General Secretariat of the Council Permanent Representatives Committee/Council Employment, Social
More informationIMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Anke M. Schulte, Sanofi-Diabetes 30.09.2014 IMI Open Info Day 2014 Brussels, Belgium General T1DM disease facts
More informationAlzheimer Europe. European Collaboration on Dementia
Alzheimer Europe European Collaboration on Dementia Members Care Manual Audience: Informal caregivers Analysis of existing information and data Tips for carers Available on AE website and in DE, FR, IT,
More informationThesis for doctoral degree (Ph.D.) 2007 Molecular epidemiology of pneumococcal carriage and invasive disease Karin Sjöström.
Thesis for doctoral degree (Ph.D.) 2007 Thesis for doctoral degree (Ph.D.) 2007 Molecular epidemiology of pneumococcal carriage and invasive disease Karin Sjöström Molecular Epidemiology of Pneumococcal
More informationAngola: Regulations on HIV/AIDS, Employment, and Professional Training (Decree 43/03 of 4 July) (2003)
Angola: Regulations on HIV/AIDS, Employment, and Professional Training (Decree 43/03 of 4 July) (2003) Adopted on 4 July 2003 and promulgated by the President of Angola on 20 April 2003. Its full name
More informationHealth related issues in Moldova. Stanislav Groppa, MD, PhD, Prof., Acad. Victor Vovc, MD, PhD, Prof.
Health related issues in Moldova Stanislav Groppa, MD, PhD, Prof., Acad. Victor Vovc, MD, PhD, Prof. Health Research institutions network of the Republic of Moldova SUMPh Nicolae Testemitanu Mother and
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Group A Streptococcal Disease, invasive (igas) Revised Group
More informationRecent and on-going WGS initiatives and activities of EFSA
Recent and on-going WGS initiatives and activities of EFSA Valentina Rizzi BIOCONTAM UNIT, EFSA 2 nd course on bioinformatics tools for Next Generation Sequencing data mining: use of bioinformatics tools
More informationScottish Medicines Consortium
Scottish Medicines Consortium escitalopram, 5mg, 10mg, and 20mg tablets and 10mg/ml oral drops (Cipralex) No. (406/07) Lundbeck Ltd 7 September 2007 The Scottish Medicines Consortium has completed its
More informationAnonymous responses from organisations ID code Country Page 1944 France 18
Funding agency, policy-maker & regulator respondees Responses from organisations ID code Organisation Country Page 1627 European Alliance for Restless Legs Syndrome Netherlands 2 1727 Royal Dutch Society
More information